Evidence map›Paper›PMID 40960488›Full record

ArticleCancer research2025

Spatial Cross-talk Modeling of the Tumor Microenvironment Identifies CCR5-Mediated Glia-to-Glia Signaling as a Key Regulator of Brain Metastatic Progression.

Ju Young Ahn, Wenjuan Dong, Akshjot Puri, Matthew Vasquez, Raksha Raghunathan, Li Yang, Jianting Sheng, Hong Zhao, Stephen T C Wong

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ju Young AhnSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0002-0946-4157
Wenjuan DongSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0009-0004-3237-2041
Akshjot PuriHouston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0001-7187-7561
Matthew VasquezSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0001-9319-2686
Raksha RaghunathanSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0002-2434-425X
Li YangSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0003-1421-7377
Jianting ShengSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0003-3532-3259
Hong ZhaoSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0001-8991-7824
Stephen T C WongSystems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.ORCID 0000-0001-9188-6502

Funding

Spatiotemporal modeling of cancer-niche interactions in breast cancer bone metastasisU01CA253553 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC, ZHANG, XIANG · 2020 to 2024
$3.0M
Systematic identification of astrocyte-tumor crosstalk regulating brain metastatic tumorsR01CA238727 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC, ZHAO, HONG · 2020 to 2024
$2.6M
Houston Methodist HospitalJohn S. Dunn Foundation (Dunn Foundation)National Cancer Institute (NCI) R01CA238727National Cancer Institute (NCI) U01CA253553NCI NIH HHS R01 CA238727NCI NIH HHS U01 CA253553Ting Tsung and Wei Fong Chao Family Foundation
6 · The paper itself

Abstract

Glial cells play a critical role in shaping the tumor microenvironment in brain metastases (BM), facilitating disease progression through complex tumor-glial cell and distinct glia-to-glia signaling pathways. To investigate these interactions, we performed RNA sequencing of astrocytes, microglia, and oligodendrocytes at various stages of brain metastatic progression, combined with spatial transcriptomics and cell-cell cross-talk analysis. Glial cells not only converged on tumor-promoting pathways such as Ras and Gap junction signaling in tumor cells but also engaged in distinct autocrine and paracrine signaling critical for interglial communication. Unique ligand-receptor pairs, including OSM-OSMR, CCL4-CCR5, CXCL16-CXCR6, IL1A/B-IL1R, and TNF-TNFR, functioned as key drivers of interglial cross-talk, which sustained the tumor-supportive niche. Therapeutic targeting of CCL4-CCR5 signaling with maraviroc, an FDA-approved antiviral drug, significantly reduced BM progression without exerting direct cytotoxic effects on tumor cells. These findings highlight a promising therapeutic strategy that focuses on modulating glial communication within the tumor microenvironment. By disrupting the supportive glial niche rather than targeting tumor cells directly, this represents a distinct and potentially less toxic approach for managing BMs. SIGNIFICANCE: Glial cells are masterminds of brain metastasis that orchestrate tumor-supportive signals and can be targeted with maraviroc to disrupt the metastatic niche as a safe and effective strategy to halt metastatic progression.

Indexed as

Brain NeoplasmsNeurogliaReceptors, CCR5Tumor MicroenvironmentAnimalsCell CommunicationCell Line, TumorDisease ProgressionHumansMaravirocMiceSignal TransductionCCR5 protein, humanMaravirocReceptors, CCR5

Identifiers

PMID40960488
PMCPMC12656220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.